Volume 2 | Issue 1 | DOI: https://doi.org/10.33696/cardiology.2.010
Predicting COVID-19 Hospitalized Patients’ Outcome with Homocysteine
Giovanni Ponti1,*, Marco Manfredini2, Gabriella Oliva3, Tomris Ozben4,5, Caterina Fontana6, Aldo Tomasi1
- 1Discipline of Pharmacology, School of Pharmacy, University of the Western Cape, Bellville 7535, South Africa
- 2Department of Chemistry, University of the Western Cape, Bellville 7535, South Africa
- 3South African Herbal Science and Medicine Institute, University of the Western Cape, Bellville 7535, South Africa
- 4Discipline of Pharmaceutics, School of Pharmacy, University of the Western Cape, Bellville 7535, South Africa
- 5Department of Chemistry, University of the Western Cape, Bellville 7535, South Africa
- 6Geriatric and Gerontology Department, University of Modena and Reggio Emilia, Modena MO, Italy
Prof. Giovanni Ponti, firstname.lastname@example.org
Received Date: March 08, 2021
Accepted Date: May 21, 2021
Ponti G, Manfredini M, Oliva G, Ozben T, Fontana C, Tomasi A. Predicting COVID-19 Hospitalized Patients’ Outcome with Homocysteine. J Clin Cardiol. 2021; 2(1):19-22.
Copyright: © 2021 Ponti G, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Homocysteine (Hcy), COVID-19 vulnerability, Predictor parameters, MTHFR gene, Biomarkers, MTHFR677C>T mutations
The COVID-19 pandemic has provoked a global, rapid increase of cases due to the high infectivity of the etiological agent, COVID-19 virus. In February 2021, over 110 million confirmed COVID-19 cases with 1 million deaths were reported worldwide (www.who.int).
The COVID-19 pandemic started at the end of 2019 and remains carrying a health threat and significant economic consequences. Over the last two years, COVID-19 has been the main Public Health issue, and has impacted regular healthcare systems, with significant build-up of waiting lists and delay in optimum management of other serious medical conditions including heart diseases and cancer.
Prevalence of Cardiovascular Risk Factors in Osteoarthritis Patients Derived from Primary Care Records: A Systematic Review of Observational Studies
Health intelligence on the frequency of cardiovascular disease (CVD) and its risk factors identifies targets and populations for preventative strategies and allows evaluation of health outcomes, behaviors and interventions in populations and health care settings.
Detection of Undiagnosed Elevated Cardiovascular Risk Biomarkers among HIV-Positive Patients on Antiretroviral Therapy (ART) in Kigali-City, Rwanda
Similar to other African countries, life expectancy of people living with HIV infection has improved due to access to antiretroviral therapy (ART) in Rwanda. However, both HIV infection and use of ART are associated with cardiovascular disease (CVD) risks, due to adverse changes in some biomarkers, causing dyslipidemia and other metabolic imbalances. Biomarkers for CVD risk in HIV-infected individuals taking ART, has not been well characterized in Rwanda.